Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
Resmed (NYSE:RMD) has achieved significant milestones in innovation with its AirTouch N30i nasal cradle mask winning two Red Dot Awards in Product Design 2025. The mask, launched in October 2024, features the company's first-ever nasal cushion combining fabric with silicone, designed to enhance CPAP therapy comfort and adherence.
The AirTouch N30i received perfect user ratings for comfort features in a multi-center study. This innovation contributes to treating obstructive sleep apnea (OSA), which affects over one billion people globally. Additionally, Resmed announced reaching 10,000 patents and designs in its global portfolio, highlighting its leadership in sleep and respiratory care technology.
Resmed (NYSE:RMD) ha raggiunto importanti traguardi nell'innovazione: il suo AirTouch N30i nasal cradle mask ha conquistato due Red Dot Awards per il Product Design 2025. Lanciata nell'ottobre 2024, la maschera introduce il primo cuscinetto nasale dell'azienda che combina tessuto e silicone, studiato per migliorare comfort e adesione alla terapia CPAP.
Lo AirTouch N30i ha ottenuto valutazioni massime dagli utenti per le caratteristiche di comfort in uno studio multicentrico. Questa innovazione sostiene il trattamento dell'apnea ostruttiva del sonno (OSA), condizione che interessa oltre un miliardo di persone nel mondo. Resmed ha inoltre annunciato di aver raggiunto 10.000 brevetti e design nel suo portfolio globale, ribadendo la sua leadership nelle tecnologie per il sonno e la cura respiratoria.
Resmed (NYSE:RMD) ha conseguido hitos importantes en innovación: su mascarilla nasal AirTouch N30i ganó dos Red Dot Awards en Product Design 2025. Lanzada en octubre de 2024, la mascarilla presenta el primer cojín nasal de la compañía que combina tela y silicona, diseñado para mejorar el confort y la adherencia a la terapia CPAP.
El AirTouch N30i obtuvo calificaciones perfectas de los usuarios en cuanto a comodidad en un estudio multicéntrico. Esta innovación contribuye al tratamiento de la apnea obstructiva del sueño (OSA), que afecta a más de mil millones de personas en todo el mundo. Además, Resmed anunció haber alcanzado 10.000 patentes y diseños en su cartera global, subrayando su liderazgo en tecnologías para el sueño y el cuidado respiratorio.
Resmed (NYSE:RMD)는 혁신 분야에서 큰 성과를 거두었습니다. 자사의 AirTouch N30i nasal cradle mask가 Product Design 2025에서 두 개의 Red Dot Awards를 수상했습니다. 2024년 10월 출시된 이 마스크는 직물과 실리콘을 결합한 회사 최초의 비강 쿠션을 적용해 CPAP 치료의 편안함과 순응도를 높이도록 설계되었습니다.
AirTouch N30i는 다기관 연구에서 편안함 항목에 대해 사용자로부터 만점 평가를 받았습니다. 이 혁신은 전 세계 10억 명 이상에게 영향을 미치는 폐쇄성 수면무호흡증(OSA) 치료에 기여합니다. 또한 Resmed는 글로벌 포트폴리오에서 10,000건의 특허 및 디자인을 달성했다고 발표하며 수면 및 호흡기 케어 기술 분야의 선도적 위치를 강조했습니다.
Resmed (NYSE:RMD) a franchi d'importantes étapes en matière d'innovation : son AirTouch N30i nasal cradle mask a remporté deux Red Dot Awards Product Design 2025. Lancé en octobre 2024, le masque intègre le premier coussinet nasal de la société combinant tissu et silicone, conçu pour améliorer le confort et l'adhérence à la thérapie CPAP.
L'AirTouch N30i a reçu des notes parfaites des utilisateurs pour les éléments de confort dans une étude multicentrique. Cette innovation contribue au traitement de l'apnée obstructive du sommeil (AOS), qui touche plus d'un milliard de personnes dans le monde. Par ailleurs, Resmed a annoncé avoir atteint 10 000 brevets et designs dans son portefeuille mondial, soulignant son leadership dans les technologies du sommeil et des soins respiratoires.
Resmed (NYSE:RMD) hat bedeutende Innovationsmeilensteine erreicht: seine AirTouch N30i nasal cradle mask gewann zwei Red Dot Awards im Product Design 2025. Die im Oktober 2024 eingeführte Maske verfügt über das erste nasale Kissen des Unternehmens, das Stoff und Silikon kombiniert und so den Komfort sowie die Therapietreue bei der CPAP-Behandlung verbessern soll.
Das AirTouch N30i erhielt in einer multizentrischen Studie bei Komfortmerkmalen perfekte Nutzerbewertungen. Diese Innovation unterstützt die Behandlung der obstruktiven Schlafapnoe (OSA), die weltweit mehr als eine Milliarde Menschen betrifft. Zudem gab Resmed bekannt, in seinem globalen Portfolio 10.000 Patente und Designs erreicht zu haben und unterstreicht damit seine Führungsposition in der Schlaf- und Atemwegstechnik.
- None.
- None.
Milestones underscore Resmed’s leadership and commitment to delivering life-changing health technology that people love
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards: Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed's first-ever nasal cushion made from fabric fused with silicone, designed to deliver both clinical performance and a therapy experience that feels more natural and comfortable making it easier for people to start and stick with CPAP therapy.
Launched in October 2024, the AirTouch N30i builds on Resmed’s legacy of product leadership. The mask combines Resmed’s patented ComfiSoft™ fabric cushion and a fabric-wrapped frame designed to deliver softness and breathability without sacrificing performance. Its layered design is intended to help release heat and moisture while maintaining a secure seal for effective therapy. As part of Resmed’s Freedom category, it also features a top-of-head hose connection and 360-degree rotating elbow to give users more freedom of movement during sleep.
Obstructive sleep apnea (OSA) affects more than one billion people worldwide1. This chronic condition can significantly disrupt daily life and increase the risk of serious health issues, including high blood pressure, diabetes, heart disease, and stroke2. Resmed’s innovations, like the AirTouch N30i, are designed to help patients stay on therapy thereby closing gaps in care. In a multi-center study with experienced CPAP users, users rated AirTouch N30i 10 out of 10 for feeling cooler, softer, more breathable, and less sweaty than their own masks3.
“At Resmed, we design with the patient experience at the center—where clinical performance and human-centered design intersect,” said Justin Leong, Chief Product Officer at Resmed. “This recognition reinforces our belief that patients shouldn’t have to compromise between therapy efficacy and comfort. When we create technology that patients love to use, we can help drive higher adherence, better outcomes, and ultimately, healthier lives.”
Resmed’s innovation leadership is also reflected in having a global portfolio of 10,000 patents and designs, granted or pending, a milestone that underscores the company’s long-standing leadership in sleep and respiratory care and its investment in technologies that empower patients and providers alike. This achievement also reflects Resmed’s future-focused strategy to drive innovation, protect core solutions, and expand global access by ensuring innovations reach the patients who need them most.
The Red Dot Award is judged by an independent panel of 43 experts from 21 countries. The award honors outstanding products that demonstrate excellence across four dimensions: quality of function, seduction, use, and responsibility.
This is the second major design award for the AirTouch N30i. In September 2024, the mask received the Australian Good Design Award in the Product Medical and Scientific category. This award, one of the longest-running and most prestigious international design programs, celebrates excellence in design that improves quality of life and drives innovation.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
| For Media | For Investors |
| Caela Shay | Salli Schwartz |
| Caela.shay@resmed.com | Salli.Schwartz@resmed.com |
| news@resmed.com | investorrelations@resmed.com |
1 Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pépin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PMID: 31300334; PMCID: PMC7007763
2 Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021; 144(3): e56-e67.
3 ResMed conducted an external, 90-day, take-home study of the AirTouch N30i mask with 120 adults who had been on PAP therapy for OSA (≥ 6 months) and were using either the AirFit N30i or DreamWear nasal masks. The study took place at two sites in the U.S. from May 31 to November 6, 2023.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/36a89391-bcfb-40b7-9dc4-edf80d2a3d51
FAQ
What awards did Resmed's AirTouch N30i win in 2025?
How many patents and designs does Resmed (NYSE:RMD) have in its portfolio?
What are the key features of Resmed's AirTouch N30i mask?
How did users rate the AirTouch N30i mask in clinical studies?
How many people are affected by obstructive sleep apnea (OSA) globally?
